Literature DB >> 1346134

Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation.

M A Kjelsberg1, S Cotecchia, J Ostrowski, M G Caron, R J Lefkowitz.   

Abstract

Mutations in an intracellular region of the alpha 1B-adrenergic receptor constitutively activate the receptor, resulting in G protein coupling in the absence of agonist, as evidenced by elevated levels of polyphosphoinositide hydrolysis. Remarkably, all 19 possible amino acid substitutions at a single site in this region (alanine 293) confer constitutive activity. This set of mutated receptors exhibits a graded range of elevated biological activities, apparently representing a spectrum of receptor conformations which mimic the "active" state of the wild type receptor. In addition to their constitutive activities, these mutated receptors all demonstrate a higher affinity for agonists, another primary characteristic of the "active" conformation of G protein-coupled receptors. The fact that all possible mutations at this particular site result in increased activity suggests that this region may function to constrain the G protein coupling of the receptor, a constraint which is normally relieved by agonist occupancy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346134

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  81 in total

1.  Constitutively active mutants of 5-HT4 receptors are they in unique active states?

Authors:  S Claeysen; M Sebben; C Bécamel; M L Parmentier; A Dumuis; J Bockaert
Journal:  EMBO Rep       Date:  2001-01       Impact factor: 8.807

Review 2.  Naturally occurring mutations of the luteinizing-hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors.

Authors:  A C Latronico; D L Segaloff
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

3.  Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay.

Authors:  C Parnot; S Bardin; S Miserey-Lenkei; D Guedin; P Corvol; E Clauser
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 4.  Thyrotropin receptor mutations in thyroid diseases.

Authors:  P M Yen
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

5.  Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides.

Authors:  Lidija Covic; Amy L Gresser; Joyce Talavera; Steven Swift; Athan Kuliopulos
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

6.  Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis.

Authors:  A Chen; Z G Gao; D Barak; B T Liang; K A Jacobson
Journal:  Biochem Biophys Res Commun       Date:  2001-06-15       Impact factor: 3.575

7.  Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors.

Authors:  H E Hopkinson; M L Latif; S J Hill
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

8.  Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Authors:  S M Nielsen; L Z Nielsen; S A Hjorth; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 9.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 10.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.